For CytoDyn (CYDY), the rules regarding what happens to executive options in a buyout are primarily governed by the Amended and Restated 2012 Equity Incentive Plan and specific executive employment agreements.
Based on the most recent filings (including Dr. Lalezari’s 2024 agreement and 2026 option grants), here is the breakdown of how CytoDyn handles unvested options during a "Change in Control" (buyout):
1. The "Double-Trigger" Standard
CytoDyn generally uses a double-trigger mechanism for its senior leadership. This means that a buyout alone does not automatically vest all options. Instead, two things must happen:
A Change in Control: The company is bought out or undergoes a major shift in ownership (typically >50%).
Qualifying Termination: Within 12 months of that buyout, the executive is terminated "Without Cause" or resigns for "Good Reason" (e.g., their role is diminished or they are forced to relocate).
If both occur, the unvested options typically become 100% vested and exercisable.
2. Discretion of the Board (The "Buyer’s Choice"
Under the 2012 Plan, the Board or its Compensation Committee has significant flexibility during a buyout. If a company acquires CytoDyn, they can choose to:
Assume or Substitute: The buyer replaces CytoDyn options with their own company's options of equivalent value. In this case, the original vesting schedule usually stays in place to keep the team motivated.
Cash-Out and Cancel: The Board can decide to cancel all outstanding options in exchange for a cash payment equal to the "spread" (the difference between the buyout price and the option's exercise price).
3. Performance-Based Units (PSUs)
For executives holding PSUs (Performance-Based Restricted Stock Units), the rules are slightly different. In a buyout:
A prorated portion of the PSUs typically converts into time-based units.
The number of units is usually based on how much of the "Performance Period" has passed up to the date of the buyout.
These converted units then follow the same "double-trigger" acceleration rules mentioned above.
4. Recent Data: The CEO's 2026 Grant
In March 2026, CEO Jacob Lalezari was granted nearly 4.87 million options at an exercise price of $0.28.
Normal Vesting: 25% vests in March 2027, with the rest vesting monthly through 2030.
In a Buyout: If a larger pharma company were to acquire CytoDyn before 2027, these 4.87 million options would not automatically vest unless the buyer chose not to "assume" them, or if Lalezari were let go following the deal.
Note for CYDY Holders: Because many of the current executive options have strike prices near $0.28, a buyout at a significant premium (e.g., $1.00 or $2.00) would represent a massive incentive for the team to complete a deal, even with "double-trigger" protections.
Based on the most recent filings (including Dr. Lalezari’s 2024 agreement and 2026 option grants), here is the breakdown of how CytoDyn handles unvested options during a "Change in Control" (buyout):
1. The "Double-Trigger" Standard
CytoDyn generally uses a double-trigger mechanism for its senior leadership. This means that a buyout alone does not automatically vest all options. Instead, two things must happen:
A Change in Control: The company is bought out or undergoes a major shift in ownership (typically >50%).
Qualifying Termination: Within 12 months of that buyout, the executive is terminated "Without Cause" or resigns for "Good Reason" (e.g., their role is diminished or they are forced to relocate).
If both occur, the unvested options typically become 100% vested and exercisable.
2. Discretion of the Board (The "Buyer’s Choice"
Under the 2012 Plan, the Board or its Compensation Committee has significant flexibility during a buyout. If a company acquires CytoDyn, they can choose to:
Assume or Substitute: The buyer replaces CytoDyn options with their own company's options of equivalent value. In this case, the original vesting schedule usually stays in place to keep the team motivated.
Cash-Out and Cancel: The Board can decide to cancel all outstanding options in exchange for a cash payment equal to the "spread" (the difference between the buyout price and the option's exercise price).
3. Performance-Based Units (PSUs)
For executives holding PSUs (Performance-Based Restricted Stock Units), the rules are slightly different. In a buyout:
A prorated portion of the PSUs typically converts into time-based units.
The number of units is usually based on how much of the "Performance Period" has passed up to the date of the buyout.
These converted units then follow the same "double-trigger" acceleration rules mentioned above.
4. Recent Data: The CEO's 2026 Grant
In March 2026, CEO Jacob Lalezari was granted nearly 4.87 million options at an exercise price of $0.28.
Normal Vesting: 25% vests in March 2027, with the rest vesting monthly through 2030.
In a Buyout: If a larger pharma company were to acquire CytoDyn before 2027, these 4.87 million options would not automatically vest unless the buyer chose not to "assume" them, or if Lalezari were let go following the deal.
Note for CYDY Holders: Because many of the current executive options have strike prices near $0.28, a buyout at a significant premium (e.g., $1.00 or $2.00) would represent a massive incentive for the team to complete a deal, even with "double-trigger" protections.
7
